Teduglutide, a glucagon-like peptide-2 analogue (REVESTIVE), in the treatment of short bowel syndrome with dependence on home parenteral nutrition

2021 ◽  
Vol 75 (2) ◽  
pp. 170-172
Author(s):  
František Novák
2020 ◽  
Vol 2 (4) ◽  
Author(s):  
Zeinab Bakhshi ◽  
Siddhant Yadav ◽  
Bradley R Salonen ◽  
Sara L Bonnes ◽  
Jithinraj Edakkanambeth Varayil ◽  
...  

Abstract Background We sought to estimate the incidence of home parenteral nutrition (HPN) use in a population-based cohort of patients with Crohn disease (CD), and to assess clinical outcomes and complications associated with HPN. Methods We used the Rochester Epidemiology Project (REP) to identify residents of Olmsted County, who were diagnosed with CD between 1970 and 2011, and required HPN. Results Fourteen out of 429 patients (3.3%) with CD received HPN (86% female). Eleven patients (79%) had moderate–severe CD and 12 patients (86%) had fistulizing disease. Thirteen patients (93%) underwent surgery, primarily due to obstruction. Among CD incidence cases, the cumulative incidence of HPN from the date of CD diagnosis was 0% at 1 year, 0.5% at 5 years, 0.8% at 10 years, and 2.4% at 20 years. Indications for HPN included short bowel syndrome in 64%, malnutrition in 29%, and bowel rest in 21%. The median duration of HPN was 2.5 years. There was an average weight gain of 1.2 kg at 6 months, an average weight loss of 1.4 kg at 1 year, and a further weight loss of 2.2 kg at 2 years from the start of HPN. Patients were hospitalized a mean of 5 times after the start of HPN, mainly due to catheter-related bloodstream infections and thrombosis. Conclusions Less than 4% of patients with CD need HPN. Most have moderate to severe disease with short bowel syndrome or malnutrition. Possible reasons for the patients’ weight loss could be noncompliance, and increased metabolic needs because of active disease.


2003 ◽  
Vol 124 (2) ◽  
pp. 293-302 ◽  
Author(s):  
David Seguy ◽  
Kouroche Vahedi ◽  
Nathalie Kapel ◽  
Jean–Claude Souberbielle ◽  
Bernard Messing

2014 ◽  
Vol 58 (4) ◽  
pp. 438-442 ◽  
Author(s):  
Antonella Diamanti ◽  
Andrea Conforti ◽  
Fabio Panetta ◽  
Giuliano Torre ◽  
Manila Candusso ◽  
...  

2019 ◽  
pp. 817-825 ◽  
Author(s):  
A. CINKAJZLOVÁ ◽  
Z. LACINOVÁ ◽  
J. KLOUČKOVÁ ◽  
P. KAVÁLKOVÁ ◽  
H. KRATOCHVÍLOVÁ ◽  
...  

The aim of our study was to assess the presence and degree of intestinal leakage in subjects suffering from short bowel syndrome (SBS) and its modification by parenteral nutrition. To this end we assessed circulating levels of selected makers of intestinal permeability including zonulin, fatty acid binding protein 2 (FABP-2), citrulline and glucagon-like peptide 2 (GLP-2). We also measured lipopolysaccharide binding protein (LBP) as a marker of circulating levels of lipopolysaccharide acting through the CD14 molecule. Eleven SBS and 10 age- and BMI-matched control subjects were included into the study. The effect of parenteral nutrition was assessed after 14 days, 6 and 12 months from its initiation, respectively. At baseline, SBS patients had increased gut permeability as measured by zonulin (47.24±2.14 vs. 39.48±1.20 ng/ml, p=0.006) and LBP (30.32±13.25 vs. 9.77±0.71 µg/ml, p<0.001) compared to healthy controls. Furthermore, SBS subjects had reduced FABP-2, unchanged citrulline and increased sCD14 and GLP-2 relative to control group. Throughout the whole study period the administered parenteral nutrition had no significant effect on any of the studied parameters. Taken together, our data show that patients with short bowel syndrome have increased intestinal permeability that is not affected by parenteral nutrition.


Sign in / Sign up

Export Citation Format

Share Document